As regards the IDH1 status, no statistically significant differences were found in the degree of [18F]FDOPA uptake between IDH1 mutant and IDH1 wildtype patients (p = 0.79), according to the results of the study by Cicone et al., with a slightly higher number of patients in our analysis (43 vs. 31) [10]; our results are also in contrast with the previous report of Verger et al. [9], in which a paradoxically higher [18F]FDOPA uptake in IDH mutant glioma was shown. The gene discussed is IDH2; the disease is central nervous system cancer.